Pfizer's updated COVID-19 booster significantly revved up adults' virus-fighting antibodies, the company said Friday, releasing early findings from a rigorous study of the new shots.
Booster doses tweaked to target the most common omicron strain rolled out in early September, and the Food and Drug Administration said the latest data should spur more Americans to get one - especially before another expected wave of cases as people travel for Thanksgiving.
A hint: A month after receiving the new booster, antibody levels in people 55 and older had jumped 13 times higher than before the extra dose. Younger adults saw a 9.5-fold jump, Pfizer and its partner BioNTech said. It had been about 11 months since the study participants' last vaccination. So the new data "reassures us that this was a good decision to move to this bivalent vaccine," FDA vaccine chief Dr. Peter Marks told The Associated Press. "Right now is the time for people to consider going out and get the updated" booster.
The updated doses are combination shots, tailored to offer a boost of protection against both the original coronavirus strain and the dominant BA.5 strain. Pfizer's shot is available for anyone 5 or older. Moderna's version of the updated booster is for those 6 and older.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, BioNTech start COVID-flu combination vaccine studyU.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
Read more »
Pfizer, BioNTech launch phase 1 trial on combined COVID-19 and flu vaccinePfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday.
Read more »
Pfizer says new Covid booster works better against omicron strains than old one in studyPfizer Inc.’s bivalent vaccine bolstered protective antibodies against the dominant omicron strains substantially more than its original booster in people older than 55, according to a compan…
Read more »